Compared with individualized medical therapy, ARNIs further reduced NT-proBNP level by 16% at 12 weeks after treatment, and they also significantly reduced the risk of first hospitalization for HF by 51% and of composite events (HF hospitalization, mortality) by 36%. This evidence concerns the gene NPPB and hydrops fetalis.